March 13, 2017
TiGenix’s hearth attack study confirms the long term safety
TiGenix has found in its acute hearth attack study that allogenic cardiac stem cells can be transplanted safely through the coronary tree.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: TiGenix
March 9, 2017
TiGenix’s Chron’s disease treatement Cx601 consistent after two years study
TiGenix’s study of Cx601 showed that results after two years are consistent with the results communicated at week 24 and week 52, said Dr Marie Paule Richard, Chief Medical Officer of TiGenix.
March 7, 2017
TiGenix’s ammended trial for Cx601 Chron’s disease accepted in US, kicks off in next four months
Belgian-headquartered biopharmaceutical company TiGenix has received positive feedback from the U.S. Food and Drug Administration (FDA) for its improved phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients.
March 6, 2017
TiGenix waits for final EMA nod for its Crohn’s disease drug
TiGenix has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Crohn’s disease drug Cx601 in 2017.
February 17, 2017
Takeda, TiGenix’s orphan drug test meets endpoint
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
February 6, 2017
TiGenix to present results of Crohn`s disease drug trial at ECCO
TiGenix will present results from its Phase III trial of Crohn`s disease drug, named Cx601, at the upcoming 12th Annual Congress of the…
January 31, 2017
TiGenix kicks off Sepcell trial to test new pneumonia treatment
TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
January 9, 2017
Takeda notifies 4.48% shareholding in TiGenix
On January 4, 2017, TiGenix received a transparency notification from related companies Takeda Pharmaceutical Company Limited/Takeda Pharmaceuticals International AG, following…
December 23, 2016
TiGenix submits Day 120 Responses to EMA for Crohn`s disease drug
TiGenix has submitted its responses to the European Medicines Agency`s (EMA) Day 120 List of Questions for Cx601, its lead…
December 21, 2016
Takeda makes EUR10 million equity investment in TiGenix
Belgian based biopharmaceutical company TiGenix has exercised the option granted by Takeda under the licensing agreement to make a EUR10…